article thumbnail

Valor Compounding Pharmacy™ is the Choice for Hormone Testing and Balancing

BioTech 365

Valor Compounding Pharmacy™ is the Choice for Hormone Testing and Balancing Valor Compounding Pharmacy™ is the Choice for Hormone Testing and Balancing Saliva testing kits, available to order online, allow patients to test their hormone levels from the comfort of … Continue reading →

article thumbnail

MEDISCA Pledges $100,000 to Alliance for Pharmacy Compounding (APC) National Media Campaign to Help Protect Compounded Hormone Therapy Medications.

BioTech 365

MEDISCA Pledges $100,000 to Alliance for Pharmacy Compounding (APC) National Media Campaign to Help Protect Compounded Hormone Therapy Medications. MEDISCA Pledges $100,000 to Alliance for Pharmacy Compounding (APC) National Media Campaign to Help Protect Compounded Hormone Therapy Medications. PLATTSBURGH, N.Y.–(BUSINESS

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading pharmaceutical compounding companies in contract marketing

Pharmaceutical Technology

Increasing drug failure rates and essential drug shortages have driven the growth of the compounding pharmacies market, which has a high growth potential, especially in emerging economies. Discover the top pharmaceutical compounding companies in contract marketing.

Marketing 130
article thumbnail

University of Illinois at Chicago's new breast cancer drug is safe and can halt disease progression, according to a Phase 1 trial

The Pharma Data

The drug is being developed and tested by researchers at the University of Illinois at Chicago and is a type of hormone therapy, which targets oestrogen receptor-positive types of breast cancer. The doses of the therapy given were in line with therapeutic levels that are standard in hormone therapy. Conor Kavanagh.

article thumbnail

Enzalutamide by Pfizer for Relapsed Multiple Myeloma: Likelihood of Approval

Pharmaceutical Technology

Enzalutamide is under development for the treatment of non-metastatic castration-resistant prostate cancer, prostate cancer in patients with non-metastatic biochemical recurrence in the EU, China and Asia, and also for metastatic hormone-sensitive prostate cancer in the U.S,

Hormones 113
article thumbnail

Enzalutamide by Pfizer for Myelofibrosis: Likelihood of Approval

Pharmaceutical Technology

Enzalutamide is under development for the treatment of non-metastatic castration-resistant prostate cancer, prostate cancer in patients with non-metastatic biochemical recurrence in the EU, China and Asia, and also for metastatic hormone-sensitive prostate cancer in the U.S,

Hormones 100
article thumbnail

Enzalutamide by Pfizer for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Pharmaceutical Technology

Enzalutamide is under development for the treatment of non-metastatic castration-resistant prostate cancer, prostate cancer in patients with non-metastatic biochemical recurrence in the EU, China and Asia, and also for metastatic hormone-sensitive prostate cancer in the U.S,

Hormones 100